VOR

Vor Biopharma Inc

18.03

Oct 16 • 3:59 PM ET -1.31 (-6.77%)

18.02

Aftermarket • 7:30 PM ET -0.01 (-0.06%)

Healthcare Biotechnology USA Small NASD

Peers: IDYA RCUS TNGX CGON CRNX BMRN KYMR RYTM INCY KRYS

| Held by: VTI XBI IWM VXF FESM IWO VTWO SCHA IWC IWN

Scroll to Statements

Index	RUT
Market Cap	1.07B
Enterprise Value	603.45M
Income	627.78M
Sales	0.00M
Book/sh	-3.68
Cash/sh	7.88
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	76
IPO	Feb 05, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	2.29
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	19.15
Current Ratio	19.15
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-83.39
EPS next Y	-3.65
EPS next Q	-0.85
EPS this Y	89.70%
EPS next Y	49.75%
EPS next 5Y	61.59%
EPS past 3/5Y	-14.82% -21.58%
Sales past 3/5Y	- -
EPS Y/Y TTM	69.48%
Sales Y/Y TTM	-
EPS Q/Q	99.54%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	-64.82% -

Insider Own	45.18%
Insider Trans	-2.89%
Inst Own	62.58%
Inst Trans	20.54%
ROA	182.91%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-5.69%
SMA50	-16.32%
SMA200	5.93%
Trades

Shs Outstand	54.46M
Shs Float	32.43M
Short Float	24.10%
Short Ratio	8.08
Short Interest	7.81M
52W High	31.31 -42.41%
52W Low	6.50 177.38%
Volatility	6.48% 6.97%
ATR (14)	1.28
RSI (14)	38.40
Beta	1.87
Rel Volume	0.76
Avg Volume	967.66K
Volume	735,159

Perf Week	-9.40%
Perf Month	-17.63%
Perf Quarter	3.32%
Perf Half Y	8.68%
Perf YTD	37.84%
Perf Year	-37.96%
Perf 3Y	-59.39%
Perf 5Y	-94.17%
Perf 10Y	-
Recom	1.33
Target Price	39.00
Prev Close	19.34
Price	18.03
Change %	-6.77%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-30-26	Initiated	Jefferies	Buy	$50
Mar-19-26	Initiated	Wells Fargo	Overweight	$30
Jan-09-26	Initiated	Citigroup	Buy	$50
Dec-17-25	Initiated	TD Cowen	Buy
Dec-09-25	Initiated	JP Morgan	Overweight	$43
Nov-25-25	Resumed	Wedbush	Neutral	$9
Oct-15-25	Upgrade	Robert W. Baird	Neutral → Outperform	$64
Sep-24-25	Upgrade	Stifel	Hold → Buy	$55
Jun-30-25	Upgrade	H.C. Wainwright	Neutral → Buy	$3
Jul-26-22	Initiated	Wedbush	Outperform	$18
Apr-27-22	Initiated	Goldman	Neutral	$6
Dec-17-21	Initiated	H.C. Wainwright	Buy	$26
Dec-03-21	Initiated	Robert W. Baird	Outperform	$38
Dec-02-21	Initiated	Oppenheimer	Outperform	$30
Oct-19-21	Initiated	JMP Securities	Mkt Outperform	$40
Mar-25-21	Initiated	B. Riley Securities	Buy	$60
Mar-03-21	Initiated	Evercore ISI	Outperform	$48
Mar-03-21	Initiated	Barclays	Overweight	$56
Mar-02-21	Initiated	Stifel	Buy	$58
Mar-02-21	Initiated	Goldman	Sell	$19

Show Previous Ratings

Oct-05-26 06:00PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-29-26 08:05AM	Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis (GlobeNewswire)
Sep-08-26 07:00AM	Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis (GlobeNewswire)
Sep-04-26 04:05PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-01-26 08:00AM	Vor Bio To Participate in Upcoming September Conferences (GlobeNewswire)
09:30AM	Loading…
Aug-11-26 09:30AM	Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-03-26 04:30PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-07-26 04:01PM	Vor Bio Appoints David Zaccardelli to Board of Directors (GlobeNewswire)
Jul-02-26 05:30PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.96%
Jun-08-26 08:31AM	Telitacicept Receives NMPA Approval for the Treatment of Sjogren's Disease in China (GlobeNewswire)
08:30AM	Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China (GlobeNewswire)
Jun-01-26 05:00PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.25%
May-28-26 08:30AM	Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-26 08:30AM	Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine (GlobeNewswire) -5.28%
May-13-26 08:30AM	Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
04:30PM	Loading…
May-04-26 04:30PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.21% +5.51%
Apr-01-26 05:00PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-30-26 08:01AM	Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjogren's Disease (GlobeNewswire)
Mar-27-26 08:00AM	Vor Bio Announces $75 Million Private Placement with TCGX (GlobeNewswire) +6.71%
Mar-23-26 04:30PM	Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.40%
Feb-23-26 08:00AM	Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference (GlobeNewswire) +13.80%
Jan-06-26 08:00AM	Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.30%
Jan-02-26 03:22PM	Getty Images, Torm, and More Stocks See Action From Activist Investors (Barrons.com) -11.01%
Dec-23-25 04:01PM	Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors (GlobeNewswire) +7.39%
Dec-15-25 08:00AM	Vor Bio Announces $150 Million Private Placement (GlobeNewswire) +7.99%
Nov-26-25 08:41AM	Vor Bio assumed with a Neutral at Wedbush (TipRanks)
Nov-25-25 12:00PM	Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-13-25 04:01PM	Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-10-25 09:56PM	Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock (GlobeNewswire) -47.66%
04:01PM	Loading…
04:01PM	Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock (GlobeNewswire)
Nov-08-25 11:45AM	Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China (GlobeNewswire)
Nov-07-25 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-03-25 08:00AM	Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer (GlobeNewswire) -7.05%
Oct-31-25 04:30PM	Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-29-25 11:01AM	Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data (GlobeNewswire) -5.29%
Oct-22-25 04:30PM	Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjogren's Disease (GlobeNewswire)
Oct-17-25 08:15AM	Vor Bio announces Phase 3 study on telitacicept in SLE met primary endpoint (TipRanks)
08:00AM	Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025 (GlobeNewswire)
Oct-16-25 08:00AM	Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine (GlobeNewswire)
Oct-14-25 08:00AM	Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjogren's Disease at ACR 2025 (GlobeNewswire)
Oct-03-25 04:01PM	Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-29-25 07:00AM	Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjogren's Disease Clinical Study at ACR Convergence 2025 (GlobeNewswire) +18.65%
Sep-23-25 08:00AM	Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer (GlobeNewswire) +11.97%
Sep-17-25 04:15PM	Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM (GlobeNewswire)
Sep-12-25 04:15PM	Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire) -8.05%
Sep-02-25 08:00AM	Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel (GlobeNewswire)
Aug-27-25 01:21PM	Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial (Benzinga)
08:00AM	Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy (GlobeNewswire)
Aug-26-25 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 04:35PM	Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +21.69%
08:30AM	Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor (GlobeNewswire)
08:30AM	Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjogren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor (GlobeNewswire)
07:00AM	Vor says drug licensed from RemeGen succeeded in Sjögrens study (BioPharma Dive)
Aug-04-25 08:30AM	Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer (GlobeNewswire)
Jul-29-25 09:35AM	Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board (Insider Monkey)
Jul-21-25 08:30AM	Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors (GlobeNewswire) -7.24%
Jul-20-25 12:35AM	H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target (Insider Monkey)
Jul-18-25 04:00PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14% -7.24%
Jul-17-25 08:30AM	Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer (GlobeNewswire) +12.26%
Jul-10-25 04:00PM	Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer (GlobeNewswire) -9.06% +8.23%
Jul-01-25 04:00PM	Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.73%
Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks) +52.83%
Jun-26-25 11:22AM	Vor, with new CEO, changes course to target autoimmune disease (BioPharma Dive) +60.53%
02:00AM	PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement (Business Wire)
Jun-25-25 04:50PM	Vor Bio Announces $175 Million Private Placement (GlobeNewswire) +74.28%
04:45PM	Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset (GlobeNewswire)
May-08-25 08:30AM	Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value (GlobeNewswire) -70.12%
Apr-30-25 02:00AM	PureTech Announces Annual Results for Year Ended December 31, 2024 (Business Wire)
Mar-20-25 05:01PM	Vor Biopharma files for $350M mixed securities shelf (SeekingAlpha)
04:05PM	Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update (GlobeNewswire)
Feb-13-25 08:00AM	Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials (GlobeNewswire)
Feb-03-25 08:00AM	Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) -5.63%
Jan-27-25 09:55AM	Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross (Zacks) -5.12%
Jan-08-25 09:00AM	Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors (GlobeNewswire)
Dec-28-24 09:27AM	Vor Biopharma Secures $55.6M for Cancer Therapy Trials (TipRanks)
Dec-27-24 02:43PM	Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47% (GuruFocus.com) +51.55%
09:00AM	Vor Bio Announces $55.6 Million Private Placement (GlobeNewswire)
Dec-09-24 07:30AM	Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design (GlobeNewswire) +26.89%
Nov-12-24 08:00AM	Vor Bio to Participate in the Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-07-24 04:05PM	Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire) +14.85%
Sep-30-24 07:00AM	Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer (GlobeNewswire)
Sep-06-24 02:00AM	PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies (Business Wire) +10.06%
Sep-05-24 04:01PM	New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies (GlobeNewswire)
Aug-28-24 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 04:05PM	Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
Aug-02-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.98% -7.51%
Jul-09-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.69%
May-13-24 09:22AM	Oppenheimer Adjusts Vor Biopharma Price Target to $10 From $15, Maintains Outperform Rating (MT Newswires)
May-09-24 10:54PM	VOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024 (InvestorPlace) -5.52%
04:05PM	Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
May-06-24 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-03-24 04:01PM	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 04:01PM	Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors (GlobeNewswire)
Apr-04-24 08:32AM	Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock (Zacks)
Apr-01-24 08:00AM	Vor Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.17%
Mar-20-24 09:53PM	VOR Stock Earnings: Vor Biopharma Beats EPS for Q4 2023 (InvestorPlace) +8.89%
04:05PM	Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update (GlobeNewswire)

Vor Biopharma, Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. It is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

ChairmanDr. Jean-Paul Kress M.D.

Chief Business Officer & CFOMr. Sandesh Mahatme L.L.M.

M.D.Dr. Robert Ang M.B.A.

M.D.Dr. Siddhartha Mukherjee DPHIL

General CounselMs. Adi Osovsky

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Oct 02 '26	Option Exercise	12.80	500	6,400	500	Oct 05 06:52 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Aug 24 '26	Option Exercise	3.74	1,500	5,604	1,500	Aug 26 06:28 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Jul 16 '26	Sale	19.75	213	4,207	4,501,882	Jul 21 04:54 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Apr 22 '26	Sale	15.77	165,150	2,604,416	2,402,095	Apr 24 06:12 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Apr 17 '26	Sale	16.28	458,411	7,462,931	2,739,208	Apr 21 07:04 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Apr 20 '26	Sale	15.77	171,963	2,711,857	2,567,245	Apr 21 07:04 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Apr 13 '26	Sale	16.15	530,610	8,569,352	3,404,998	Apr 15 05:29 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Apr 14 '26	Sale	15.97	153,735	2,455,148	3,251,263	Apr 15 05:29 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Apr 15 '26	Sale	16.01	53,644	858,840	3,197,619	Apr 15 05:29 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Apr 08 '26	Sale	16.48	484,104	7,977,786	4,071,637	Apr 10 06:23 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Apr 09 '26	Sale	16.59	135,201	2,242,985	3,936,436	Apr 10 06:23 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Apr 10 '26	Sale	15.75	828	13,041	3,935,608	Apr 10 06:23 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Apr 06 '26	Sale	16.59	589,257	9,777,898	4,555,741	Apr 06 06:51 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Apr 02 '26	Sale	18.23	260,000	4,741,066	5,144,998	Apr 06 06:51 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 29 '25	Sale	25.22	251,518	6,343,284	804,231	Oct 30 06:40 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 28 '25	Sale	27.42	124,311	3,408,230	1,055,749	Oct 30 06:40 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 30 '25	Sale	25.12	24,579	617,424	779,652	Oct 30 06:40 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 27 '25	Sale	28.12	90,941	2,557,261	1,180,060	Oct 27 08:04 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 23 '25	Sale	28.01	76,880	2,153,409	1,324,346	Oct 27 08:04 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 24 '25	Sale	28.01	53,345	1,494,193	1,271,001	Oct 27 08:04 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 20 '25	Sale	29.67	92,023	2,730,483	0	Oct 22 07:48 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 21 '25	Sale	28.11	25,027	703,509	1,401,226	Oct 22 07:48 PM
Reprogrammed Interchange LLC	10% Owner	Oct 20 '25	Sale	30.05	11,616	349,101	1,167,109	Oct 21 05:45 PM
Reprogrammed Interchange LLC	10% Owner	Oct 21 '25	Sale	30.07	200	6,015	1,166,909	Oct 21 05:45 PM
RA Capital Nexus Fund, L.P.	Director	Oct 20 '25	Proposed Sale	29.43	15,104	444,511		Oct 20 05:01 PM
RA Capital Healthcare Fund LP	Director	Oct 20 '25	Proposed Sale	29.43	76,919	2,263,726		Oct 20 04:52 PM

VOR

Vor Biopharma Inc

Upgrade your Finviz experience